Evidence map›Paper›PMID 25655250›Full record

SynthesisDrugs2015

Pemphigus vulgaris: an evidence-based treatment update.

Cathy Y Zhao, Dedee F Murrell

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 56 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. IgGBiomedicines · 2022
    Article
  11. Article
  12. Review
  13. Management of Pemphigus in COVID-19 Pandemic Era; a Review Article.Archives of academic emergency medicine · 2020
    Review
  14. Pemphigus vulgaris.Anais brasileiros de dermatologia · 2019
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Emerging treatment options for the management of pemphigus vulgaris.Therapeutics and clinical risk management · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Cathy Y ZhaoDepartment of Dermatology, St George Hospital, Gray St, Sydney, NSW, 2217, Australia.
Dedee F Murrell
St George Hospital · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile a variety of intervention options have been described for pemphigus vulgaris, the optimal treatment strategy has not been established.

objectivesThe objective of this systematic review is to assess the literature on the efficacy and safety of interventions for the treatment of pemphigus vulgaris. DATA SOURCES: Five electronic databases were searched, including The Cochrane Skin Group's Specialized Register, The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE and Latin American and Caribbean Health science Information database (LILACS). Five trial registers as well as reference lists of included RCTs were also searched. STUDY ELIGIBILITY CRITERIA: Any published randomised controlled trial (RCT) on intervention for pemphigus vulgaris was included, provided the diagnosis of pemphigus vulgaris was confirmed with appropriate clinical features, histopathology and immunofluorescence studies. Studies which included forms of pemphigus other than pemphigus vulgaris were excluded.

interventionsAltogether 18 RCTs were identified including 16 distinct interventions. STUDY APPRAISAL AND SYNTHESIS

methodsIncluded studies were assessed for patient selection, methods of randomisation, blinding, follow-up and selective reporting.

resultsCurrent evidence is incomplete and inconclusive. The interventions which appear promising, but will require further evaluation include adjuvant mycophenolate mofetil (MMF), azathioprine, intravenous immunoglobulins (IVIG), sulfasalazine and pentoxifylline, infliximab, epidermal growth factor and pimecrolimus. Interventions with inconclusive evidence include high (120-180 mg) versus low (45-60 mg) prednisone dosage, pulsed dexamethasone, cyclophosphamide, dexamethasone-cyclophosphamide pulse therapy (DCP), cyclosporine, dapsone, etanercept, acyclovir and tacrolimus. LIMITATIONS: Our review is limited by the small number of high-quality RCTs and variety of outcome measures, precluding the performing of a meta-analysis. CONCLUSIONS AND IMPLICATIONS OF KEY

findingsThe optimal treatment strategy for pemphigus vulgaris remains unclear. Higher quality RCTs are required in the future to re-evaluate many interventions and to explore other unstudied interventions.

Indexed as

Randomized Controlled Trials as TopicAnti-Inflammatory Agents, Non-SteroidalDose-Response Relationship, DrugGlucocorticoidsHumansImmunologic FactorsPemphigusTreatment OutcomeAnti-Inflammatory Agents, Non-SteroidalGlucocorticoidsImmunologic Factors

Identifiers

PMID25655250
OpenAlexW2029001556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.